COMMISSIONED AND CERTIFIED, APRIL 2013
News and Events
- InterVac Certification Achieved - Apr 22, 2013
- Former VIDO Director, Dr. Lorne Babiuk, wins 2013 Killam Prize in Health Sciences - Apr 11, 2013
- PREVENT and VIDO sign collaborative agreement with South China United Vaccine Institute and Guangzho Institute of Respiratory Disease - Mar 28, 2013
- VIDO-InterVac scientists receive $1M in Agriculture Funding - Jan 24, 2013
InterVac Overview
Click for our new InterVac video!
When InterVac becomes operational in 2012, research capabilities within VIDO-InterVac will grow exponentially.
InterVac will alleviate the current worldwide shortage of Containment Level 3 laboratory space for vaccine research and development.
Our research addresses infectious diseases of importance to human and animal health, and involves:
- developing new vaccines and improving existing ones
- improving methods for administering vaccines in both animals and humans
- improving the safety of food and water
- providing international calibre training for graduate students and scientists from around the world
Benefits of InterVac
For Society:
- Canada’s strategy for dealing with infectious diseases will be strengthened.
- Working with the Public Health Agency of Canada and the Canadian Food Inspection Agency, Canada will be able to respond faster to emerging diseases affecting animals and humans.
For Researchers:
- Understanding of CL3 infectious diseases and the interactions between human and animal health will be better understood.
- InterVac's distinctive design will accommodate research ranging from preclinical testing to licensing trials.
For Animal and Human Health Industries:
- Agricultural and biopharmaceutical industries that address animal and human health issues will be enhanced.
- R&D on infectious diseases of agricultural and economic significance will be strengthened.
For Saskatchewan and Canada:
- InterVac will provide unparalleled research, teaching and graduate study opportunities.
- Saskatchewan’s international leadership in vaccine development will be secured.
- About 400 construction jobs and 50 full-time research-related employment positions will be added to the province.
Funding for InterVac Construction
Funding has been provided by:
- Government of Canada
- Government of Saskatchewan
- City of Saskatoon
- Last hour animated
- Last 24 hours animated
- Time lapse from start of construction
Grand Opening Celebration
The grand opening celebration for InterVac took place on Friday, September 16th and included the Right Honourable Stephen Harper, Prime Minister of Canada; the Honourable Brad Wall, Premier of Saskatchewan; His Worship Donald Atchison, Mayor or Saskatoon and special guests from industry, government and accademia.
Event sponsors for the grand opening celebration included:
- Alberta Prion Research Institute
- Alberta Innovates Bio Solutions
- Bioniche Life Sciences Inc.
- BIOTECanada
- Canada Foundation for Innovation
- Canada's RX&D
- Cangene
- CEVA
- GlaxoSmithKline
- Merck
- Prevtec Microbia
- Sanofi Pasteur
A video of the grand opening event can be viewed here.
